Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of a cord blood transplant using OTS and to see
how well it works in treating patients with human immunodeficiency virus (HIV) positive
hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white
blood cells, can take a while to recover, putting the patient at increased risk of infection.
OTS consists of blood stem cells that help to produce mature blood cells, including immune
cells. Drugs used in chemotherapy, such as fludarabine, cyclophosphamide, and thiotepa, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Total body irradiation is a type of
whole-body radiation. Giving chemotherapy and total-body irradiation before a cord blood
transplant with OTS may help to kill any cancer cells that are in the body and make room in
the patient's bone marrow for new stem cells to grow and reduce the risk of infection.
Phase:
Phase 2
Details
Lead Sponsor:
Fred Hutchinson Cancer Research Center
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)